Key Action Statement Profile: KAS 6B
| Aggregate evidence quality | Grade B |
| Benefits | Reduced risk of influenza infection. Reduction in frequency of AOM associated with influenza. |
| Risks, harms, cost | Potential vaccine adverse effects. Cost of vaccine. Requires annual immunization. |
| Benefits-harms assessment | Preponderance of benefit. |
| Value judgments | Potential vaccine adverse effects are minimal. |
| Intentional vagueness | None |
| Role of patient preferences | Some parents may choose to refuse the vaccine. |
| Exclusions | See CDC guideline on contraindications (http://www.cdc.gov/flu/professionals/acip/shouldnot.htm). |
| Strength | Recommendation |
| Aggregate evidence quality | Grade B |
| Benefits | Reduced risk of influenza infection. Reduction in frequency of AOM associated with influenza. |
| Risks, harms, cost | Potential vaccine adverse effects. Cost of vaccine. Requires annual immunization. |
| Benefits-harms assessment | Preponderance of benefit. |
| Value judgments | Potential vaccine adverse effects are minimal. |
| Intentional vagueness | None |
| Role of patient preferences | Some parents may choose to refuse the vaccine. |
| Exclusions | See CDC guideline on contraindications (http://www.cdc.gov/flu/professionals/acip/shouldnot.htm). |
| Strength | Recommendation |